Kristine R. Crews currently serves as the Director of Research Operations in the Department of Pharmacy and Pharmaceutical Sciences at St. Jude Children’s Research Hospital and is Director of an ASHP-Accredited PGY2 Residency in Clinical Pharmacogenomics. She completed her doctorate in pharmacy at Rutgers University, followed by residency and fellowship training in clinical pharmacokinetics/pharmacodynamics at the University of Kentucky and the University of North Caroline Chapel Hill.
Crews is a Fellow of the American College of Clinical Pharmacy. She is a founding member of the Clinical Pharmacogenetics Implementation Consortium and serves as an author for CPIC guidelines. Crews has been recognized with the ASHP Research and Education Foundation Innovation in Pharmacy Practice Literature Award and the HOPA Oncology Pharmacy Practice Literature Award for her contributions to the literature.
Her research interests include pediatric oncology clinical trials and the clinical implementation of pharmacogenomics to individualize treatment regimens for children with cancer.
Crews recognizes that the Clinical Pharmacogenomics Program at St. Jude is an area seeing enormous growth, as discovery research findings are taken into the clinic to optimize the care of patients. There is a need for clinician researchers conducting translational research to bridge the laboratory findings and patient care.
“As St. Jude expands, there will be new roles for clinician researchers who are skilled in designing, conducting, and reporting clinical investigations to advance cures. The skills gained through the Master of Science in Clinical Investigation program will enable me to contribute to analyzing and publishing results of clinical investigations to advance knowledge.”
BS - Rutgers, The State University of New Jersey, New Brunswick
PharmD - Rutgers, The State University of New Jersey, New Brunswick
Residency - Clinical Pharmacokinetics, University of Kentucky Medical Center, Lexington
Fellowship - Clinical Pharmacokinetics/Pharmacodynamics and Drug Development, University of North Carolina School of Pharmacy, Chapel Hill and Glaxo Wellcome, Inc., Research Triangle Park, North Carolina
Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, Cavallari LH, Muller DJ, Prows CA, Nagy M, Somogyi AA, Skaar TC. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther 110:888-96, 2021. PMID: 33387367.
Morris SA, Crews KR, Hayden RT, Takemoto CM, Yang W, Baker DK, Broeckel U, Relling MV, Haidar CE. Incorporating genotyping to identify patients with G6PD deficiency. Pharmacogenetics and Genomics. 2022 Apr 1;32(3):87-93. PMID: 34693927
Jeha S, Crews KR, Pei D, Peyton M, Panetta JC, Ribeiro RC, Zhao X, Campbell P, Metzger ML, Yang JJ, Cheng C, Pui CH, Bhojwani D. Phase I study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer 127:2074-82, 2021. PMID: 33598942.